SHAREHOLDER ALERT: MPLN FGEN WPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ALERT: MPLN FGEN WPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Friday, May 28, 2021 10:25 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 28, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Multiplan Corporation F/K/A Churchill Capital Corp. Iii (NYSE:MPLN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/multiplan-corporation-f-k-a-churchill-capital-corp-iii-loss-submission-form?prid=16315&wire=1
Lead Plaintiff Deadline: June 7, 2021
Class Period: July 12, 2020 - November 10, 2020

Allegations against MPLN include that: (a) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan's largest customers, UnitedHealthcare, which threatened up to 35% of the Company's sales and 80% of its levered cash flows by 2022; (b) sales and revenue declines in the quarters leading up to the Merger were not due to "idiosyncratic" customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan's services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; (c) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan's services and balanced billing practices, causing the Company's to cut its take rate by up to half in some cases; (d) as a result of (a)-(c) above, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; (e) as a result of (a)-(d) above, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and (f) as a result of (a)-(e) above, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan's business was worth far less than represented to investors.

FibroGen, Inc. (NASDAQ:FGEN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16315&wire=1
Lead Plaintiff Deadline: June 11, 2021
Class Period: October 18, 2017 - April 6, 2021

Allegations against FGEN include that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Washington Prime Group, Inc. (NYSE:WPG)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/washington-prime-group-inc-loss-submission-form?prid=16315&wire=1
Lead Plaintiff Deadline: July 23, 2021
Class Period: November 5, 2020 - March 4, 2021

Allegations against WPG include that: (1) WPG's financial condition was deteriorating substantially; (2) as a result, there was substantial uncertainty about the Company's ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

The Law Offices of Vincent Wong
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions